respiratori
virus
carv
common
caus
upper
andor
lower
respiratori
tract
infect
urti
lrtd
allogen
stem
cell
transplant
result
high
morbid
mortal
especi
lower
respiratori
tract
recent
introduct
daili
clinic
practic
sophist
diagnost
tool
base
revers
transcript
polymeras
chain
reaction
test
carv
pathogen
permit
expand
microbiolog
find
bronchoalveolar
lavag
bal
recipi
harbor
lower
respiratori
tract
lrt
complic
fact
like
increas
abil
diagnos
infecti
pneumonia
probabl
led
identif
high
number
case
compar
convent
microbiolog
studi
ie
viral
cultur
antigen
test
avail
carv
current
lack
studi
analyz
detail
incid
characterist
consequ
pathogen
lrt
set
carv
lrtd
studi
report
presenc
agent
time
carv
lrtd
may
increas
overal
howev
still
unknown
extent
increas
mortal
could
attribut
aggress
concurr
pathogen
elucid
issu
clinic
outcom
comparison
carv
lrtd
carv
lrtd
ie
bacteri
pneumonia
suitabl
better
establish
put
effect
microbiolog
outcom
purpos
studi
analyz
clinic
implic
viral
fungal
bacteri
carv
lrtd
detect
bal
sampl
cohort
recipi
carv
lrtd
episod
compar
outcom
carv
bacteri
lrt
monoinfect
addit
analyz
risk
factor
rf
valu
immunodefici
score
index
isi
predict
morbid
mortal
recipi
carv
lrtd
era
observ
retrospect
studi
includ
consecut
recipi
n
develop
infecti
lower
respiratori
tract
complic
underw
bal
sampl
microbiolog
studi
januari
decemb
two
spanish
transplant
center
case
select
detail
figur
focus
recipi
free
diseas
time
bal
whose
bal
sampl
screen
carv
n
overal
recipi
includ
form
hospit
hospit
universitario
la
patient
divid
group
group
recipi
first
proven
carv
lrtd
diagnos
bal
specimen
n
without
microbiolog
agent
detect
bal
group
recipi
first
proven
carv
lrtd
detect
virus
n
group
recipi
carv
lrtd
n
group
recipi
first
proven
carv
lrtd
provenprob
pulmonari
invas
aspergillosi
ia
n
respect
group
recipi
first
episod
bacteri
pneumonia
n
exclud
case
summar
figur
variabl
immunodefici
score
index
isi
basel
immunodefci
grade
cmv
dnaemia
requir
antivir
therapi
cmv
carv
lrtd
radiolog
pulmonari
pattern
oxygen
support
requir
maintain
oxygen
satur
immunosuppress
drug
corticosteroid
dose
presenc
sign
symptom
acut
chronic
graft
versu
host
diseas
gvhd
requir
intens
care
unit
icu
admiss
captur
patient
chart
day
hospit
admiss
andor
bal
perform
sinc
immunoglobulin
g
level
avail
time
bal
patient
adapt
basel
immunodefici
grade
score
follow
moder
sever
sever
immunodefici
statu
accord
presenc
none
one
follow
variabl
respect
hsct
month
deplet
month
graft
diseas
gvhd
grade
extens
diseas
neutropenia
x
lymphopenia
x
microbiolog
find
bal
sampl
radiolog
pattern
also
collect
critic
review
local
ethic
committe
approv
studi
avail
subject
gave
written
inform
consent
particip
studi
bronchoscopi
perform
use
standard
procedur
accord
intern
consensu
carv
test
bal
sampl
perform
multiplex
platform
hcuv
sampl
test
use
luminex
xtag
rvp
fast
assay
luminex
molecular
diagnost
toronto
canada
wherea
hlf
pneumovir
dna
array
assay
genomica
coslada
spain
perform
interpret
follow
manufactur
recommend
technic
methodolog
previous
report
detail
luminex
xtag
rvp
fast
assay
detect
adenovirus
adv
human
bocaviru
hbov
human
coronaviru
cov
type
influenza
viru
infa
infa
virus
influenza
b
viru
infb
human
metapneumoviru
hmpv
b
human
parainfluenza
viru
hpiv
respiratori
syncyti
viru
rsv
enterovirusrhinoviru
evrh
pneumovir
dna
array
assay
differ
luminex
xtag
rvp
fast
assay
detect
influenza
c
viru
allow
detect
alphacoronaviru
viru
betacoronavirus
pneumovir
abl
discrimin
rhinoviru
enteroviru
genu
permit
identif
new
influenza
overal
technic
show
compar
sensit
detect
quantit
cultur
bal
specimen
bacteri
isol
perform
convent
media
agreement
gener
accept
bacteri
load
cfuml
deem
clinic
relev
bal
specimen
cultur
agar
bd
becston
dickinson
mycobacteria
growth
indic
tube
agar
slant
sabouraud
agar
recoveri
legionella
pneumophila
mycobacterium
spp
fungal
organ
respect
aspergillu
ag
kit
hercul
ca
usa
use
quantit
aspergillu
spp
galactomannan
calcofluor
white
blue
toluidin
direct
immunofluoresc
stain
procedur
use
detect
pneumocysti
jiroveci
cmv
dna
plasma
quantifi
use
realtim
cmv
pcr
assay
abbott
molecular
de
plain
il
usa
exhibit
limit
detect
approxim
iuml
hcuv
previous
hlf
cmv
biomerieux
letoil
pari
franc
display
limit
detect
iuml
surveil
cmv
dnaemia
quantit
conduct
least
week
within
first
day
outpati
visit
immunosuppress
center
preemptiv
antivir
therapi
approach
use
hcuv
prevent
cmv
patient
preemptiv
treat
oral
valganciclovir
iv
ganciclovir
iv
foscarnet
upon
detect
cmv
dna
level
exceed
iuml
cmv
dna
doubl
time
day
previous
turn
univers
prophylaxi
strategi
use
hlf
decemb
briefli
relat
recipi
given
oral
valganciclovir
mgd
three
time
week
day
transplant
unrel
recipi
treat
oral
valganciclovir
mgd
day
transplant
detect
level
cmv
dna
plasma
prompt
administr
antivir
therapi
val
ganciclovir
foscarnet
dose
specifi
januari
preemptiv
strategi
carri
upon
detect
cmv
dnaemia
level
cmv
defin
describ
acut
graft
versu
host
diseas
agvhd
diagnos
grade
accord
standard
confirm
carv
lrtd
defin
accord
recent
consensu
lrt
consid
addit
clinic
signific
microbiolog
agent
includ
bacteri
fungal
andor
carv
specimen
also
detect
bal
sampl
except
staphylococcu
aureu
staphylococcu
spp
deem
agent
well
streptococcu
spp
ie
streptococcu
viridan
enterococcu
spp
ie
enterococcu
faecali
e
faecium
consid
put
causat
bacteri
pneumonia
pathogenet
signific
bacteria
identifi
bal
sampl
term
mix
flora
use
yeast
belong
candida
spp
consid
agent
contrast
probableproven
pulmonari
ia
diagnos
time
carv
lrtd
consid
fungal
detect
cmv
dna
bal
consid
entiti
studi
sinc
quit
common
phenomenon
interpret
still
recipi
receiv
antibiot
carbapenem
cefepim
case
hemodynam
instabl
akimacin
ad
time
microbiolog
result
antimicrobi
therapi
adapt
accordingli
primari
object
studi
describ
clinic
microbiolog
characterist
carv
lrtd
well
evalu
effect
subtyp
clinic
outcom
carv
lrtd
compar
respiratori
viru
bacteri
secondari
end
point
includ
identif
rf
bacteri
caus
mortal
day
bal
sampl
recipi
carv
lrtd
frequenc
compar
use
test
fisher
exact
test
categor
variabl
differ
median
compar
use
u
test
univari
multivari
analys
associ
clinic
microbiolog
rf
bacteri
overal
mortal
calcul
use
cox
regress
model
includ
covari
appropri
multivari
analysi
variabl
paramet
estim
show
p
valu
univari
analysi
final
includ
exact
p
valu
report
p
valu
consid
statist
signific
probabl
mortal
carv
lrtd
estim
cumul
incid
curv
treat
diseas
relaps
compet
event
probabl
os
cumul
incid
plot
mortal
estim
time
bal
use
univari
comparison
done
data
analyz
spss
version
statist
packag
r
cran
project
surviv
design
prodlim
cmprsk
detail
clinic
characterist
subject
carv
lrtd
wo
bacteri
pneumonia
shown
tabl
patient
allograft
februari
juli
note
patient
profound
immunosuppress
statu
recipi
includ
allograft
altern
donor
adult
unrel
donor
cord
blood
famili
donor
least
one
antigen
mismatch
donor
hla
b
c
dr
allel
determin
genotyp
clinic
biolog
characterist
carv
lrtd
shown
tabl
common
type
carv
detect
evrh
case
follow
rsv
hpiv
influenza
hmpv
adv
cov
case
carv
lrtd
occur
within
first
year
case
occur
day
stem
cell
infus
develop
lrtd
day
day
day
year
observ
signific
clinic
andor
biolog
differ
among
group
except
lower
rate
cmv
group
p
univari
multivari
analys
rf
carv
lrtd
day
caus
mortal
shown
tabl
multivari
analysi
identifi
independ
variabl
associ
increas
risk
bacteri
corticosteroid
mgkgd
hazard
ratio
hr
confid
interv
ci
p
cmv
time
bal
hr
ci
p
regard
rf
day
caus
mortal
multivari
model
identifi
variabl
associ
increas
mortal
lymphocyt
count
hr
p
occurr
cmv
time
bal
hr
ci
p
bacteri
hr
ci
p
need
oxygen
support
time
bal
hr
ci
p
base
rf
lymphocyt
count
cmv
oxygen
support
elabor
risk
score
accord
presenc
rf
figur
risk
model
predict
differenti
group
differ
mortal
rate
identifi
subgroup
patient
low
risk
mortal
irrespect
carv
lrtd
figur
overal
recipi
carv
lrtd
die
median
day
bal
rang
day
caus
mortal
respiratori
failur
attribut
lrtd
case
infect
gvhd
account
case
due
gvhd
sinusoid
obstruct
syndrom
hematolog
relaps
regard
mortal
accord
carv
type
observ
death
case
evrh
rsv
hpiv
influenza
hmpv
case
adv
final
case
cov
day
overal
surviv
group
respect
p
figur
tabl
summar
clinic
microbiolog
characterist
carv
lrtd
bacteri
group
bacteri
pneumonia
group
clinic
andor
biolog
signific
differ
among
group
term
rf
includ
isi
relev
clinic
characterist
oxygen
support
icu
admiss
case
group
identifi
bacteria
bal
wherea
group
case
bacteria
p
case
respect
found
mix
flora
bal
icu
admiss
rate
p
mortal
rate
group
respect
p
day
os
higher
group
compar
group
although
signific
reach
figur
limit
analysi
recipi
bacteria
observ
recipi
group
die
day
bal
compar
group
p
studi
herein
show
carv
lrtd
common
bacteri
pneumonia
recipi
carv
lrtd
associ
increas
mortal
also
identifi
rf
lymphopenia
cmv
need
oxygen
support
time
bal
led
stratif
risk
group
significantli
differ
mortal
rate
notabl
patient
low
risk
rf
low
mortal
rate
irrespect
presenc
agent
nucleic
acid
amplif
test
report
high
rate
carv
lrtd
consid
respiratori
viru
ia
signific
bacteri
prior
studi
era
report
lower
rate
bal
fact
limit
knowledg
regard
role
clinic
outcom
carv
lrtd
studi
report
pool
bacteremia
fungal
infect
cmv
reactiv
herp
simplex
viru
human
herpesviru
viru
significantli
increas
mortal
recipi
sever
carv
other
fail
demonstr
neg
report
lack
comparison
counterpart
studi
provid
evid
carv
lrtd
bacteri
display
neg
effect
mortal
multivari
analysi
interestingli
observ
trend
poorer
outcom
recipi
carv
lrtd
bacteri
compar
bacteri
pneumonia
find
suggest
neg
effect
bacteri
seem
independ
explain
predomin
influenc
bacteri
agent
rather
statu
limit
analysi
bacilli
also
observ
higher
mortal
carv
lrtd
bacteri
compar
bacteri
pneumonia
although
signific
reach
probabl
due
low
number
recipi
includ
anoth
relev
find
studi
identif
rf
mortal
easili
identifi
time
carv
lrtd
rf
alreadi
identifi
prognost
marker
progress
lrtd
ie
lymphopenia
sever
studi
among
differ
respiratori
viru
rf
mortal
ie
lymphopenia
oxygen
requir
cmv
rf
built
risk
score
abl
discrimin
group
differ
risk
mortal
irrespect
statu
merit
valid
studi
contrast
abl
provid
evid
clinic
use
neither
isi
score
adapt
basel
immunodefici
grade
score
predict
mortal
multivari
analysi
pool
carv
lrtd
cohort
although
isi
origin
design
rsv
valid
influenza
like
includ
isi
hamper
abil
predict
outcom
seri
fact
none
variabl
includ
isi
statist
signific
multivari
model
reflect
weak
model
cohort
fact
suggest
valid
isi
carv
warrant
routin
applic
therapeut
regard
basel
immunodefci
grade
score
fact
includ
immunoglobulin
levelsin
score
may
hamper
abil
assess
true
valu
valid
would
regard
analysi
rf
carv
lrtd
decis
limit
analysi
bacteri
justifi
main
reason
first
studi
show
bacteri
signific
neg
effect
clinic
outcom
contrast
respiratori
viru
ia
second
increas
evid
mechan
wherebi
viral
infect
enhanc
aggrav
bacteri
former
favor
growth
bacteri
agent
multipl
factor
includ
local
destruct
antibacteri
barrier
epitheli
surfac
suppress
antibacteri
immun
induct
apoptosi
immun
third
rf
respiratori
viru
expect
differ
affect
bacteri
sinc
respiratori
viru
transmiss
depend
upon
epidemiolog
situat
recipi
contact
contact
children
vaccin
statu
captur
data
base
thu
identifi
condit
relat
higher
incid
bacteri
corticosteroid
mgkgd
cmv
corticosteroid
rf
profound
immunosuppress
may
contribut
bacteri
infect
first
time
cmv
identifi
risk
factor
bacteri
pneumonia
carv
lrtd
cmv
highli
immunosuppress
may
act
synergist
respiratori
viru
favor
bacteri
growth
respiratori
tract
addit
cmv
readili
infect
macrophag
vivo
impair
abil
recogn
elimin
bacteria
anoth
contribut
factor
observ
could
develop
therapi
studi
warrant
confirm
find
sinc
use
antibiot
recipi
carv
risk
progress
lrt
concurr
cmv
andor
corticosteroid
therapi
may
clinic
use
prevent
bacteri
pneumonia
last
least
report
fungal
show
neg
effect
surviv
cohort
like
introduct
effect
drug
overcom
histor
bad
prognosi
complic
even
context
carv
lrtd
acknowledg
studi
limit
includ
rel
low
number
patient
use
differ
multiplex
pcr
platform
carv
inclus
sever
carv
type
well
retrospect
natur
addit
multipl
virus
detect
abl
differenti
infect
shed
resolv
infect
continu
detect
overcom
limit
critic
review
radiolog
pattern
time
bal
well
presenc
upper
lower
respiratori
symptom
ensur
high
degre
case
moreov
bal
sampl
homogen
prospect
test
carv
fungal
bacteri
agent
avoid
inclus
case
pcr
retrospect
test
frozen
bal
sampl
fact
consid
strength
regard
inclus
sever
type
carv
lrtd
may
differ
pathogen
sever
compar
studi
analyz
mortal
among
differ
carv
lrtd
show
similar
mortal
could
justifi
pool
cohort
analysi
mortal
fact
observ
signific
differ
mortal
among
differ
respiratori
virus
seri
either
without
addit
data
show
overal
mortal
rate
compar
among
carv
line
sever
emphas
carv
lrtd
still
common
complic
conclus
carv
lrtd
frequent
may
neg
effect
outcom
particular
context
bacteri
risk
score
base
easili
identifi
rf
lymphopenia
oxygen
requir
cmv
merit
valid
cohort
wherea
isi
basel
immunodefici
grade
requir
valid
prospect
studi
author
declar
conflict
interest
